However, this view has changedrecently, because of the attractive perspective to inhibit differentsteps of the SARS-CoV-2 life cycle with a single drug.21 Moreover, the approved HCV NS3/4A drug boceprevir,inhibiting cathepsin L by approx. 20% in our assay, demonstrates thatthe inhibition of this target in the course of viral hepatitis therapyis obviously acceptable. The gene discussed is KRAS; the disease is animal viral hepatitis.